Brief: Teva and Active Biotech announce CONCERTO trial of Laquinimod in RRMS did not meet primary endpoint
05/05/2017 19:00
May 5 (Reuters) - Teva Pharmaceutical Industries Ltd
TEVA.TA :
* Teva and Active Biotech announce CONCERTO trial of
Laquinimod in RRMS did not meet primary endpoint
* Study shows secondary endpoint which measured change in
brain volume compared to baseline was positive
* In study, secondary endpoints measuring time to confirmed
disability progression at 6, 9 months did not reach significance
* "While we have no current plans to further pursue
Laquinimod in RRMS, we are continuing to study it in two other
trials"
* Teva continues to evaluate potential of Laquinimod in
Primary Progressive MS and Huntington Disease
Source text for Eikon: ID:nBw5k7CFna
Further company coverage: ACTI.ST TEVA.TA
((Bangalore.newsroom@thomsonreuters.com;))